Section 09
Financial Projections
5-year forecast with blended revenue from all tiers
TL;DR
We start with $22K out of pocket and aim to be profitable by month 8-10. Most revenue comes from a blend: many customers on the app ($29/month) and blood work ($365/year), fewer on peptides ($149-499/month), and a small number of premium clients ($5K-50K/year) who drive the biggest share of revenue. Year 5 target is $40M revenue with 22% net profit ($8.8M). No outside investors needed — all growth funded by reinvested profits.
Year 5 Revenue
$40M
+82% from Y4
Year 5 Net Margin
22%
Profitable from Month 8-10
Break-even
Month 8-10
Self-funded to profitability
Initial Investment
$22K
Self-funded, Medvi-style
Revenue Projection (5-Year)
Margin Evolution
Customer Growth
Projected P&L
| Line Item | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|
| Revenue | $600K | $3.0M | $10.0M | $22.0M | $40.0M |
| COGS | $330K | $1.4M | $3.8M | $7.0M | $11.2M |
| Gross Profit | $270K | $1.6M | $6.2M | $15.0M | $28.8M |
| Marketing | $120K | $900K | $3.0M | $6.2M | $10.0M |
| Operations | $60K | $240K | $800K | $1.5M | $2.4M |
| Tech & Infra | $24K | $60K | $150K | $330K | $500K |
| Legal & Regulatory | $30K | $75K | $200K | $350K | $500K |
| Admin | $24K | $75K | $150K | $300K | $400K |
| EBITDA | $12K | $300K | $1.9M | $6.3M | $15.0M |
| Net Income | $12K | $300K | $1.4M | $4.0M | $8.8M |
Unit Economics Evolution
| Metric | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|
| CAC | $350 | $320 | $300 | $280 | $270 |
| LTV | $1,100 | $1,400 | $1,700 | $2,000 | $2,300 |
| LTV:CAC | 3.1x | 4.4x | 5.7x | 7.1x | 8.5x |
| ARPU | $170/mo | $185/mo | $200/mo | $210/mo | $220/mo |
| Monthly Churn | 12% | 10% | 8% | 6% | 5% |